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CHAPTER 1 
Role of the glycoprotein CD162 (PSGL-1) as a 
potential target for immunotherapy in T cell 
lymphomas 
  
Introduction 
 
Lymphomas are a heterogeneous array of cancers affecting the 
lymphoid tissue and deriving from the uncontrolled 
proliferation of lymphocytes, cells belonging to the immune 
system. Lymphomas are classically divided into Hodgkin’s 
Lymphoma (HL) and Non-Hodgkin’s Lymphomas (NHLs). 
HLs are characterized by the the presence of a peculiar type of 
cancer cell named Reed Sternberg cell. NHLs are caused by the 
clonal expansion of B cells, T cells or Natural Killer (NK) cells 
which lose the capability to perform their main functions and 
begin to progressively localize and accumulate into lymphoid 
organs. Lymph nodes, bone marrow and spleen are mainly 
involved during lymphomagenesis, however, neoplastic clones 
can often disseminate and colonize also other extranodal sites 
such as the central nervous system, skin or liver.  
Even if the basis underlying the development of lymphoid 
neoplasms still remain partially unknown, multiple risk factors 
have been linked to the occurance of lymphomas. Indeed, 
chromosomal alterations, autoimmune disorders featured by a 
chronic antigenic stimulation, immunosuppression (driven by 
virus infections or by immunosuppressive therapy regimens) 
can play a pivotal role in lymphomagenesis. 
About the 80-90% of NHLs involve B-cells and just a minority 
of cases are of T-cells origin (e.g. Peripheral T-cell 
Lymphomas), as a consequence of their low incidence T-cell 
lymphomas are not well characterized yet and often represent a	  real	   challenge	   both for the diagnostic approach and for their 
clinical management. Such features make T-cell NHLs an 
interesting field of investigation aimed to better clarify their 
pathogensis and to develop new therapeutic strategies. 
Peripheral T cell lymphomas (PTCLs) represent a 
miscellaneous group of rare hematological neoplasms, 
accounting almost for the 10-15 % of all non-Hodgkin 
lymphomas [1], that commonly share an aggressive behaviour 
and poor prognosis. Such values of incidence may follow a 
pattern of  geographical distribution since the majority of cases 
are registered in Asia compared to western countries [2] 
PTCLs arise from post-thymic T lymphocytes or mature NK 
which after the occurance of genetic alterations head towards 
anomaly in their proliferate rate. According to the most recent 
WHO classification of hematological and lymphoid 
malignancies, PTCLs are broadly divided in two categories: the 
branch of specified forms and the one of not otherwise 
specified (NOS) entities [3]. While the specified group is 
further subdivided into defined lymphoproliferative disorders 
showing characteristic genetic aberrations, typical clinical 
presentation and immunophenotype, PTCLs-NOS lack of 
distinctive features and represent the majority of PTCLs for 
which no peculiar immunophenotipic or molecular profile has 
been typified yet. PTCLs comprise forms such as anaplastic 
large T-cell lymphoma (ALCL) in its ALK+ and ALK- variants 
[4] , angioimmunoblastic T- cell lymphoma (AITL) [5], 
extranodal forms like the hepatosplenic γδ-T cell lymphoma 
(HSTL) [6] and the NK/T-cell lymphoma – nasal type [7], the 
Adult T-cell leukemia/lymphoma (ATLL) associated to HTLV-
1 infection [8]. 
Despite the overmentioned classification, peripheral T cell 
lymphomas can be characterized by: infrequency, poor 
prognosis, unresponsiveness to conventional chemotherapic 
treatments. Clinical approaches to PTCL have so far provided 
similar treatments to those used for B cell lymphomas 
(anthracyclines-based regimens as CHOP or CHOP-like), 
however, no encouraging results have been achieved and the 5 
years overall survival rate usually do not exceed the 40% of 
cases [9, 10]. 
A valid and promising therapeutic option may come from 
targeted therapies based on the use/subministration of 
monoclonal antibodies (mAbs). Once engaged their specific 
target, mAbs are able to activate immunological mediators such 
as the complement system and in turn mediate citotoxic effects 
on cancer cells. Targeting cancer cells through the use of 
monoclonal antibodies able to bind tumor associated antigens 
has contributed, in the later years, to change the approach for 
the treatment of both solid and hematological neoplasms. To 
date, several mabs have been introduced in clinical practice, 
examples are: the anti-HER2 receptor Trastuzumab for the 
treatment of HER2 positive breast cancer [11], the anti-VEGF-
A Bevacizumab for treatment of colorectal cancer [12], or the 
anti-CD20 Rituximab for the treatment of B-cell lymphomas 
[13]. Administration of mabs alone or in association with 
chemoterapic regimens have so far demonstrated a more 
accurated ability to specifically eradicate cancer clones sparing 
the normal cellular counterpart from elimination. mAbs can 
exert anti-tumor effects by mediating the activation of immune 
effectors recognizing the Fc fragment of mabs adsorbed on 
target cells, or through direct cytoxic effects. 
The immune effectors involved in tumor cell lysis are: the 
complement system which is able to mediate the so-called 
complement-dependent cytotoxicity (CDC), and cytotoxic 
effector cells including: dendritic cells [14], monocytes [15], 
natural killer (NK) cells [16], and T- cells [17; 18] mediating 
the antibody-dependent cell-mediated cytotoxicity (ADCC). 
The classical complement cascade becomes active after that its 
first component, the C1q protein, recognizes and binds to the 
Fc portion of the antibody adsorbed on target cell surface. Such 
event initiates a signaling pathway which brings, through the 
cleavege of the components C4 and C2, to the formation of the 
protein complex C3 convertase. The C3 convertase is further 
involved in the cleavege of C3 and formation of C5 convertase 
that cleaves C5. C5 finally complexes with C6, C7, C8 and C9, 
thus forming the membrane attacking complex (MAC) and 
elicitating the CDC. 
On the contrary, ADCC does not involve soluble proteins to 
kill target cells but requires effector cells to recognize and bind, 
through their Fcγ receptors (FcγRs), the Fc portion of mabs 
attached on target cell surface. The interaction between FcγRs 
and Fc causes the release of cytotoxic granules responsible for 
cell lysis. 
One of the first suitable target proposed for PTCLs treatment 
was the membrane antigen CD52, target of the mAb Campath 
(Alemtuzumab). However, due to its variable and 
heterogeneous expression on cancer cells, use of Alemtuzumab 
did not prove to be effective and the relapse rate after treatment 
is high [19; 20]. Another mAb which is currently tested in 
several clinical trials is the chimeric anti-CD30 conjugated with 
an anti-tubulin chemoterapeutic agent, the brentuximab-vedotin 
(SGN-35). PTCLs cells can else be CD30+ and share this 
feature with Hodgkin lymphoma cells. Treatments with SGN-
35 have been shown to obtain good results also in relapsed 
cases and in patients refractory to conventional 
chemotherapeutic administration [21,22] 
In 2009, our group investigated the cell adhesion molecule P-
Selectin Glycoprotein Ligand-1 (PSGL-1 , CD162) as a 
suitable candidate of immunotherapy of multiple myeloma 
[23]. 
PSGL-1 is a disulfide-linked homodimeric glycoprotein of 240 
kDa carrying two Sialyl-LewisX  groups, it’s expressed on all 
myeloid and lymphoid lineages and it acts as the ligand for all 
three selectins [24]. If opportunely sulfated on its tyrosines 
(Tyr13 and Tyr 15), PSGL-1 can drive tethering and rolling as 
well as cell extravasation [25]. Although PSGL-1 pathway has 
not been completely described, its engagement induces the 
activation of Src family kinases (SFKs), spleen tyrosine kinases 
(Syk) and p38 (belonging to the MAP kinases group) [26], its 
triggering is moreover involved in T cell homeostasis 
regulating CD8+ cells proliferation [27]. 
In light of the known expression of PSGL-1 on activated T 
cells and according to the capability of anti-PSGL-1 
monoclonal antibody to induce murine T cell death in vitro 
[28], we sought to determine if PSGL-1 could act as a potential 
target for humoral immunotherapy in PTCLs. 
Aim of this study was to evaluate PSGL-1 expression in 
PTCLs cases and the in vitro effects elicitated by treatment 
with two anti-PSGL-1 mAbs on human ALCL cell lines. We 
also investigated the role of immunological effectors able to 
mediate tumor cell lysis after the binding of the antibody to its 
target by ADCC and CDC assays. 
 
  
Materials and Methods 
 
Gene Expression Profiling Analysis 
 
Total RNA was extracted with the use of the TRIzol reagent 
(Invitrogen and Life Technologies), purified with the use of the 
RNeasy Kit (QIAGEN), and processed according to the 
Affymetrix Expression Analysis Technical Manual. 
Fragmented cRNA (15 µg) was hybridized to HG-U133 2.0 
Plus microarrays (Affymetrix). The gene expression values 
were determined by MAS 5 algorithm in Expression Console 
(Affymetrix), and normalization was performed by scaling to a 
target intensity of 500. Normalization quality control was 
performed by box-plot and MA plot consistency. 
 
Cell lines and Tissue Specimens 
 
The human ALCL cell lines SU-DHL, TS, JB6, KI-JK, SUP-
M2, KARPAS-299 and the PTCL-NOS cell line MAC were 
kindly provided by Prof G. Inghirami (Università di Torino). 
The cells were grown in RPMI-1640 medium supplemented 
with 10% heat inactivated fetal bovine serum (FBS) (Hyclone 
Laboratories, Logan, United Kingdom), 2mM glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin, and incubated at 37C° 
in 5% CO2 humidified atmosphere. 
Formalin-fixed, paraffin-embedded tissue samples from 110 
cases of ALCL and 50 cases of PTCL-NOS cases were 
collected in tissue microarrays whose sections were gently 
provided by Prof. PP Piccaluga (Università di Bologna) 
 
Tissue Microarrays 
For tissue microarray (TMA) construction, a slide stained with 
hematoxylin and eosin was prepared from each paraffin block, 
and representative tumor regions were morphologically 
identified and marked on each slide. Tissue cylinders with a 
diameter of 1.0 mm were punched from the marked areas of 
each block and brought into a recipient paraffin block using a 
precision instrument. Four-µm thick sections were cut from 
each recipient block and used immunohistochemical stains. 
 
Antibodies 
The following antibodies were used in our experiments: 
LEAF™ purified anti-human CD162 Antibody (Biolegend); 
anti-human CD162 azide-free (Immunotools); anti-human 
CD46 (Immunotools); anti-human CD55 (IBGRL Reserch 
products, Bristol, UK); anti-human CD59 (isolated by the 
Department of Bacteriology and Immunology of the 
S.Junnikkala Haartman Institute); Alexa 488-conjugated goat 
anti-mouse (Invitrogen Molecular Probes). 
 
Immunohistochemistry 
 
For in situ single-marker immunohistochemical analysis 
sections of tissue microarrays made of ALCL and PTCL-NOS 
cases were deparaffinized with xylene and rehydrated to water 
through a graded alcohol series. Antigen unmasking was 
performed using a microwave epitope retrieval technique with 
10 mmol citrate buffer (pH 9.0) at high temperature for 20 min. 
Endogenous peroxidase activity was quenched with 3% 
hydrogen peroxide. Sections were incubated with anti-human 
CD162 (Biolegend) at room temperature for 1 hour. Staining 
was performed with the Novolink Max Polymer Detection 
System (Leica Microsystems) and with DAB ( 3,3’ 
Diaminobenzidine) substrate chromogen (Leica Microsystems). 
Finally, sections were countestained with hematoxilyn. 
Slides were evaluated using a Leica DM2000 equipped with a 
Leica DFC320 digital camera. 
 
Flow Citometry 
 
Flow cytometry analysis was performed on PTCL cells using 
indirect immunofluorescent staining  Samples were analysed 
on a Becton Dickinson FACScalibur (BD Biosciences, NJ, 
USA) 
 
CDC 
 
2x105 cells were incubated with TB5 with or without blocking 
antibodies against CD46, CD55 and CD59 (2.5µg/mL) diluited 
in PBS-BSA 2% Ca2+-Mg2+  to a final volume of 100 µl for 10 
minutes at room temperature prior to addition of 25% normal 
human serum (NHS). After further incubation at 37°C for 
1hour, the number of residual viable cells was estimated using 
the MTT assay and the percentage of dead cells was calculated 
with the TECAN Infinite-200 microplate reader (TECAN). 
 
ADCC 
 
5x104 cells were washed and resuspended in 100µL of PBS and 
incubated with the lipophilic tracer FAstDil (Invitrogen) for 15 
minutes at 37°C. Not-bound dye was eliminated by 3 washes in 
PBS and cells were pelleted by centrifugation (1 minute at 
250g) and resuspended in 200 µL of RPMI-1640. Labeled cells 
were incubated with human effector cells (PBMCs, effector-to-
target ratio of 50:1) and anti-human PSGL-1 antibodies 
(2.5µg/mL) for 48 hours at 37°C.  
Non-viable cells count was obtained by calculating the release 
of FAstDil in solution with the TECAN Infinite-200 microplate 
reader (TECAN). 
 
Direct Cytotoxicity 
 
2x105 cells were incubated with anti-human PSGL-1 antibodies 
(2.5µg/mL) in 100µL RPMI-1640 for 48 hours at 37°C. The 
number of residual viable cells was estimated using the MTT 
assay and the percentage of dead cells was calculated with the 
TECAN Infinite-200 microplate reader (TECAN). 
 
Confocal Analysis 
 
105 were spotted on a cytospin slide and fixed in 3-4% 
paraformaldehyde in PBS for 15 minutes at room temperature. 
Cells were sequentially incubated with 1%BSA in PBS for 30 
minutes to block unspecific binding of the antibodies and with 
anti-human PSGL-1 antibodies (1mg/ml) for 1 hr at room 
temperature in a humidified chamber. 
Finally, cells were incubated with the Alexa 488-conjugated 
goat anti-mouse secondary antibody for 1 hr at room 
temperature in dark. 
Slides were evaluated using the Leica TCS SP5 Laser Scanning 
Confocal Microscope. 
  
Results  
 
Gene Expression Profiling Analysis reveals increasing 
levels of PSGL-1 mRNA in Anaplastic Large T cell 
lymphomas. 
 
T-cell lymphomagenesis is often followed by the aberrant 
expression of immunophenotipic markers which are tipically 
expressed by normal T cells. Consequently, T-cell 
lymphoproliferative disorders  may be associated to loss of 
CD3, CD4 and CD8, reduction of CD45 and incoherent CD79a 
and CD20 expression [29; 30; 31] On the ground of such 
evidences, we sought to determine if PSGL-1 mRNA may vary 
its level of expression in peripheral T cell neoplasms through a 
gene expression profile analysis (GEP). We collected PSGL-1 
transcripts from AITL, ALCL, ATLL, PTCL-NOS, reactive 
and normal specimens. The analysis of variance between the 
different groups of lymphoproliferative disorders demonstrated 
an overall increase of PSGL-1 mRNA in PTCLs, in particular, 
Anaplastic Large T-cell Lymphoma was found to show the 
highest expression of the transcript. GEP data prompted us to 
choose the ALCL as a prototypical setting for the evaluation of 
PSGL-1 expression in tissue samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSGL-1 is widely expressed in ALCL cases 
 
Given to the fact that a high level of tissue expression is an 
essential requirement to choose a molecule for targeted 
immunotherapy, we attempted to assess PSGL-1 expression in 
ALCL cases versus PTCL-NOS cases, chosen as our control. 
We, moreover, assessed a semi-quantitative analysis, assigning 
to each case a value ranging from score 0 to score 3+ , to 
classify all cases according to the intensity of the staining.  
110 cases of ALCL and 50 of PTCL-NOS were collected using 
the Tissue Microarray technique and immunohistochemical 
staining was performed. Taking into account the totality of 
PTCLs collected (160), we described a median score of 
intensity of 3+ (3.1% score 0, 11% score 1+; 28% score 2+, 
and 52,5%  score 3+) in the 92% of positive cases. However, 
ALCL and PTCL-NOS cases did not show the same median 
score of PSGL-1 expression that was 3+ in ALCL cases (1.8% 
score 0, 11.8% score 1+, 23.6% score 2+, and 59% score 3+) 
and 2+ in PTCL-NOS histotype (6% score 0, 10% score 1+, 
38% score 2+, and 38% score 3+). Such evidence demonstrated 
an homogeneous expression of PSGL-1 in ALCL cases (the 
94% of cases) the majority of whom displayed the highest 
intensity of positivity for PSGL-1. Immunohistochemical data 
not only confirmed the previous results obtained by GEP 
analysis but also convinced us to investigate the expression of 
PSGL-1 in ALCL human cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Anaplastic Large T Cell Lymphoma cell lines are positive 
for PSGL-1 
To further elucidate the role of PSGL-1 and to transfer our 
evidences to an “in vitro” setting, we analyzed PSGL-1 
distribution on human ALCL cell lines surface by 
cytofluorimetry. Six human ALCL cell lines bearing the t(2,5) 
and its fusion product NPM-ALK, together with a PTCL-NOS 
cell line chosen as control, were assessed for PSGL-1 
expression using two different anti-human PSGL-1 monoclonal 
antibodies: the KPL-1 and the TB5 clones. Both mabs were 
selected according to their blocking activity (KPL1) or agonist 
effect (TB5) towards PSGL-1 and their application was aimed 
to obtain insights about the effects that may arise from the 
block or activation of PSGL-1.  
In Cytofluorimetric analysis, KPL1 and TB5 clones revealed a 
comparable capability to bind their target which was overall 
expressed by each cell line analyzed. In particular, the 
expression of PSGL-1 assessed with KPL-1 and TB5 was 
respectively: 98.5% and 98.4% in TS cell line; 90.9% and 
95.9% in JB6; 91.7% and 71% in SUDHL-1; 76.2% and 44.7% 
in KARPAS-299; 55.5% and 31.9% in KI-JK; 29.2% and 
13.9% in SUP M2; 83.8% and 57.9% in our control cell line 
MAC-1 (data not shown). 
In general, KPL1 was showed to be more capable to bind 
PSGL-1 than TB5, such event was probably due to a more easy 
access for KPL1 to its binding epitope. On the basis of the 
results obtained by cytofluorimetric analysis, we set up three 
different assays to study the antibody-mediated lysis of our 
ALCL cell lines: the complement-dependent cytotoxicity 
(CDC), the antibody dependent cell-mediated cytotoxicity 
(ADCC), and the direct cytotoxicity. 
 
 
Anti-PSGL-1 mabs are able to induce antibody mediated 
cell lysis 
In light of the mabs ability to induce cell death, we set up three 
lines of experiments in vitro to evaluate the capacity of anti-
PSGL1 mabs to mediate human ALCL cell lines killing by 
means of CDC, ADCC and direct citotoxicity.  
Overall, both KPL1 and TB5 did not show an elevated capacity 
to induce a pronounced complement activation followed by a 
conspicuous CDC. In particular, KPL-1 mediated a lysis equal 
to the 8.7% in our control cell line MAC-1 (with a standard 
deviation of 4.5%), a CDC equal to the 16.5% in SUDHL-1 
(with a standard deviation if 4.4%), the 11.8% in JB6 cells 
(with a standard deviation of 6.5%), the 10.6% in TS cells 
(with a standard deviation of 4.6%), almost the 1% in KIJK 
cells (with a standard deviation of 2.16%), the 5% in SUPM2 
cells (with a standard deviation of 3.1%). No CDC was 
mediated by KPL-1 in Karpas-299 cell line. 
Alike the clone KPL-1, the binding of TB5 to PSGL-1 
elicitated a weak complement dependent citotoxicity that was 
equivalent to 19.9% in MAC-1 cell line (with a standard 
deviation of 7.1%), 15% in SUDHL-1 cells (with a standard 
deviation of 4.4%), the 3.8% in JB6 (with a standard deviation 
of 3.9%), 7.8% in TS (with a standard deviation of 4.6%), the 
9.8% in Karpas-299 (with a standard deviation of 6.4%), the 
8.6% in KIJK (with a standard deviation of 6.1%), the 7.5% in 
SUPM2 (with a standard deviation of 3.1%). 
Our results demonstrated the low ability of both mabs to fix 
complement; a partial explanation of such evidences may be 
similar to the one which underlies on the feeble complement 
dependent citoxicity mediated by rituximab which action has 
been proved to be counteracted by the presence of complement 
inhibitory proteins on the surface of CD20+ cells [32]. 
Membrane-bound complement regulatory proteins (mCRPs) 
CD46, CD55 and CD59 are capable to interfere with 
complement deposition on target cells so as to prevent the 
formation of the membrane attack complex and inhibiting cell 
lysis, tumor cells frequently express mCRPs and the use of new 
bispecific monoclonal antibodies neutralizing both mCRPs and 
tumor-associated antigens has been proposed [33; 34]. In light 
of these findings, we sought to determine if human ALCL cell 
lines express mCRPs by flow citometry, demonstrating a 
shared expression of mCRPs between the ALCL cell lines 
SUDHL-1 and TS (data not shown). Owing to the results 
obtained by FACS analysis, we repeated the CDC experiments 
using the anti-PSGL-1 clone TB5, together with antibodies able 
to neutralize the activity of mCRPs. The concurrent block of 
CD46, CD55, and CD59 produced a remarkable increase of 
cell lysis in respect to the one obtained in CDC experiments 
using the anti-PSGL-1 mab alone. Indeed, the percentage of 
tumor cells lysis ranged from 15% (obtained with the TB5 
alone) to the 24.1% in the presence of TB5 in association with 
the anti-CD46, anti-CD55 and anti-CD59 (with a standard 
deviation of 1.6%) for SUDHL-1 cells; from 7.8% in the 
presence of TB5 alone to 51.8% in the presence of TB5 in 
association with anti-CD46, anti-CD55 and anti-CD59 (with a 
standard deviation of 5.1%) for TS cells. 
These data suggest that targeting PSGL-1 can mediate tumor 
cell lysis through the activation of the complement cascade, 
however, the action of anti-PSGL-1 mabs is limited by the 
presence of mCRP on cancer cell surface. 
The second group of experiments was set up to study the ability 
of anti-PSGL-1 mabs to prime ADCC in the presence of 
effector cells with citotoxic activity. 
ADCC assays showed a different capability of anti-PSGL-1 
mabs to induce cell lysis, while treatment with mab KPL-1 was 
associated with low levels of cell death, treatment with the mab 
TB5 was associated to moderate levels of cell killing. More 
specifically, KPL-1 did not induce cell death neither in our 
control cells MAC-1, nor in Karpas-299 and in SUPM2. 
Conversely, KPL-1 induced an ADCC equal to the 17.1% in 
SUDHL-1 cells (with a standard deviation of 3.8%), the 11% in 
JB6 cells (with a standard deviation of 3.9%), the 6.8% (with a 
standard deviation if 3.9%) in TS cells, the 13.5% (with a 
standard deviation of 2.6%), the 0.3% (with a standard 
deviation of 0.44%). Otherwise than KPL-1, treatment with the 
mab TB5 led to higher levels of effector cell-mediated 
citotoxicity. TB5 produced the 7.5% of ADCC in MAC-1 (with 
a standard deviation of 4.3%), the 47.2% in SUDHL-1 (with a 
standard deviation of 11.4%), the 14.6% in JB6 (with a 
standard deviation of 11.4%), the 29.7% in TS (with a standard 
deviation of 9.8%), the 21.8% in Karpas-299 (with a standard 
deviation of 1.4%), the 31.8% in KIJK (with a standard 
deviation of 2.5%), and the 20% in SUPM2 (with a standard 
deviation of 1.4%). 
The third and last series of experiment was designed to 
investigate the role of mabs KPL-1 and TB5 to induce a direct 
citotoxic effect in the absence of immune effectors such 
complement or cells with cytotoxic activity. 
The results of our experiments, validated analyzing the fraction 
of viable cells after treatment with both KPL-1 and TB5 mAbs, 
demonstrated that TB5 was more effective in inducing cell 
lysis than KPL-1. KPL-1 determined the 12.3% of cell lysis in 
MAC-1 (with a standard deviation of 4.3 %), the 8.8% in 
SUDHL-1 (with a standard deviation of 4.4%), the 10.5% in 
JB6 (with a standard deviation of 4%), the 7.7% in TS (with a 
standard deviation of 4.7%), the 3% in KIJK (with a standard 
deviation of 3%), the 3% in SUPM2 (with a standard deviation 
of  2.7%), no lysis was promoted in Karpas-299 by KPL-1. 
TB5 clone was able to trigger the 14.9% of cell killing in 
MAC-1 (with a standard deviation of 4.5%), the 65% in 
SUDHL-1 (with a standard deviation of 10.7%), the 92% in 
JB6 (with a standard deviation of 12.4%), the 37% in TS (with 
a standard deviation of 7.6%), the 36.8% in Karpas-299 (with a 
standard deviation of 8.2%), the 24.6% in KIJK (with a 
standard deviation of 3.9%), the 27.5% in SUPM2 (with a 
standard deviation of 4.6%). 
Taken together, our data show a significant ability of TB5 to 
induce direct cytotoxic effects on tumor cell lines compared to 
KPL-1. The explanation of such relevant difference between 
KPL-1 and TB5 in inducing cell killing may be the result of a 
cross-linking of PSGL-1 on cell surface after treatment with the 
agonist TB5. The use of high titers of TB5 would lead to a 
supraliminal activation of PSGL-1 signaling pathway and could 
hesitate in the activation of the intrinsic apoptotic pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
KPL-1 and TB5 mediate different localization of PSGL-1 
on cell surface 
 
In order to demonstrate a diverse distribution of PSGL-1 
induced by KPL-1 or TB5 on cell membrane, ALCL cell lines 
were stained with both mAbs conjugated with a fluorescent 
dye. The confocal microscope analysis of the mAbs binding 
showed a noticeable discrepancy of PSGL-1 localization on 
cell surface. PSGL-1 was homogeneously deployed on cells 
after KPL-1 binding, on the contrary, TB5 mediated the 
localization of our target in specific regions of cell membrane 
thus forming a peculiar phenomenon termed as capping. The 
formation of caps is usually induced by mabs bearing agonist 
activity and can precede the initiation of a signaling pathway. 
The TB5-dependent cross-linking of PSGL-1 further 
substantiates our hypothesis according to which a more 
effective cell killing, obtained after TB5 binding, could be due 
to a pronounced activation of the PSGL-1 molecular cascade 
and in mAb driven cell apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Confocal analysis of PSGL-1 distribution after treatment with mabs 
  
Discussion 
 
The greater understanding of the biological mechanisms and 
genetic aberrations that lie behind cancer transformation, have 
provided us a clearer picture of the intratumour and 
intertumour complexity. The most recent studies have 
demonstrated that rarely malignant tumours originate from a 
single cell and that they rather are the result of a clonal 
selective pressure which brings to the collection of neoplastic 
clones characterized by an epigenetic plasticity. Indeed, both 
primary tumour and metastasis are formed by cellular 
subpopulations which play different but complementary roles 
aimed to neoplastic progression [35]. On the other hand, a deep 
diversity can be observed between neoplasms belonging to the 
same class, for instance, breast neoplasms [36] or peripheral T-
cell lymphomas [37]. PTCLs are characterized by tumour cells 
displaying not only functional and morphologic differences but 
also various immunophenotypical profiles. In light of such 
tumour heterogeneity, the development of new “tailored” 
therapies able to specifically target malignant clones and to 
spare the cellular healthy counterpart, represents a primary 
goal. In recent years, monoclonal antibodies were adopted as 
adjuvants to improve the efficacy of conventional cancer 
chemotherapy. According to the cancer immunoediting 
hypothesis tumoral spread begins as a consequence of the 
escape of neoplastic cells from immunological surveillance, 
monoclonal antibodies act as a booster of host immune system 
and mediate the specific elimination of clones by activation of 
immune effectors. Mabs mediate cell killing through the 
activation of the complement system or the stimulation of 
NK/T-cell citotocity, both immune effectors recognize the Fc 
portion of mabs attached on the surface of their target via an Fc 
receptor and promote cancer cell elimination. Beside a 
complement-dependent citotoxicity (CDC) and an antibody-
dependent cell-mediated citoxicity (ADCC), mabs can elicitate 
a direct citotoxicity which is triggered simply by the binding of 
mabs on target cell membrane. On the ground of the 
encouraging results obtained by the use of monoclonal 
antibodies for the treatment of hematological malignancies [38; 
39], we sought to determine the in vitro effects of mabs 
treatment on human PTCLs cultures. In particular, we 
investigated the efficacy of two monoclonal antibodies able to 
target the P-selectin glycoprotein ligand 1 (PSGL-1), the 
principal binding partner of selectins which is expressed on 
activated T-lymphocytes, platelets, plasmacells and monocytes. 
PSGL-1 primarily drives cell tethering and rolling but its 
activity is also implied in cell survival [19], moreover, PSGL-1 
could act as a potential target for humoral immunotherapy in 
multiple myeloma [15] .  
We first analyzed and compared the expression of PSGL-1 
mRNA between some peripheral T-cell lymphomas and normal 
tissue by gene expression profiling, finding an overall 
increased expression of our target in PTCLs especially in the 
anaplastic large cell lymphoma group (ALCL). Basing on our 
preliminary results, we chose ALCL as a prototypical model of 
investigation to test the tissue expression of PSGL-1 by 
immunohistochemistry. Immunohistochemistry was performed 
on 110 cases of ALCL and 50 of PTCL-NOS (chosen as 
control), collected with the tissue microarray technology, and 
demostrated a constant and strong expression of the marker in 
nearly all cases of ALCL examined. 
Finally, we showed a considerable ability of anti-PSGL-1 
monoclonal antibodies to induce CDC, ADCC and direct 
cytotoxicity on PTCLs cell lines.  
Taken together our experimental data demostrate that PSGL-1 
may be eligible as a potential immunotherapic target for the 
treatment of the anaplastic large cell lymphoma, however, the 
use of animal models should be auspicable since it could give 
us a deeper insight regarding the physiological effects that 
could be obtained from PSGL-1 targeting. 
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2.1 Monoclonal antibodies as carriers 
  
Introduction  
Beside the capability to induce a direct cytotoxic effect, 
monoclonal antibodies can be exploited to serve as a drug 
carrier to selectively kill tumour cells. Indeed, mabs can be 
chemically conjugated both with chemotherapeutic agents, 
that’s the case of Brentuximab Vedotin [13],  or with 
chemotherapy-loaded nanoparticles able to fuse with cancer 
cell membrane and specifically deliver drugs into it [40]. 
  
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Microenvironmental Role in Cancer 
Progression 
  
Introduction 
The role played by the microenvironment in supporting cancer 
progression was neglected in the past years and a greater 
attention was focused on tumour cell biology. In recent years 
many evidences demonstrated that both solid tumours and 
hematologic neoplasms develop in an environment enriched by 
inflammatory cells (macrophages, mast cells, T and B cells) 
and bioactive molecules (TGFβ, IL10, IFNγ) that through a 
constant crosstalk with cancer cells foster the clonal expansion. 
The study of such dynamics could provide us a clearer picture 
of cancer development. 
   
 

 
	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 MicroRNAs and Cancer	   	  
Introduction 
MicroRNAs (miRNAs) are small noncoding RNAs not longer 
than 22 nucleotides. Despite miRNAs were initially considered 
devoid of function, an increasing number of studies 
demonstrate their capability to finely regulate: proliferation, 
apoptosis, differentiation, transcriptional and post 
transcriptional events; moreover, they were proved to drive 
cancer initiation, progression and metastasis. Hence, miRNAs 
are able to play a protumorigenic role (oncomiR) or act as 
tumor suppressors [41]. 
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